News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>M Stanley Cuts GIANT BIOGENE's TP to HKD74; Rating Kept Overweight
Morgan Stanley has issued a research report estimating that GIANT BIOGENE (02367.HK) will step up its market promotion efforts to address negative publicity and regain brand moment...
Reset
Send
The window will close in 5 seconds
<Research>M Stanley Cuts GIANT BIOGENE's TP to HKD74; Rating Kept Overweight
Close
Recommend
4
Positive
6
Negative
5
 
SHORT SELL
 
STOCK INFO

Morgan Stanley has issued a research report estimating that GIANT BIOGENE (02367.HK)  -3.750 (-6.957%)    Short selling $119.87M; Ratio 15.070%   will step up its market promotion efforts to address negative publicity and regain brand momentum.

The broker revised down its 2025-27 overall sales forecasts for GIANT BIOGENE by 13%/ 9%/ 7%. Specifically, it forecasted the company's overall sales to grow by 18% in 1H25, with its brand Comfy leaping by 12%, while in 2H25, its overall sales growth would reach 20% alongside a 14% surge in Comfy.

Related NewsCMBI Recommends 3 3SBIO/ BEIGENE/ INNOVENT BIO/ GIANT BIOGENE; CN Pharmas to Face ST Pullback Pressure
Morgan Stanley lowered its target price from HKD100 to HKD74 but kept the Overweight rating unchanged, citing that the consumer preference for ingredient-oriented beauty products in China and the company's advantages in biotechnology would remain unchanged.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-06-25 12:25.)

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.